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Objectives. This study investigated the relation between gender,
etiology and survival in patients with symptomatic heart failure.
Background. Previous work provides conﬂicting results con-
cerning the relation between gender, clinical characteristics and
survival in patients with heart failure.
Methods. We examined the relation of these factors in 557
patients (380 men, 177 women) who had symptomatic heart
failure, predominantly nonischemic in origin (68%) and typically
associated with severe left ventricular dysfunction.
Results. Follow-up data were available in 99% of patients (mean
follow-up period 2.4 years, range 1 day to 10 years) after study
entry, and 201 patients reached the primary study end point of
all-cause mortality. By life-table analysis, women were signiﬁ-
cantly less likely to reach this primary end point than men (p <
0.001). A signiﬁcant association was found between female gender
and better survival (p < 0.001), which depended on the primary
etiology of heart failure (p  0.008 for the gender–etiology
interaction) but not on baseline ventricular function. Women
survived longer than men when heart failure was due to nonisch-
emic causes (men vs. women: relative risk [RR] 2.36, 95% conﬁdence
interval [CI] 1.59 to 3.51, p < 0.001). In contrast, outcome appeared
similar when heart failure was due to ischemic heart disease (men vs.
women: RR 0.85, 95% CI 0.45 to 1.61, p  0.651).
Conclusions. Women with heart failure due to nonischemic
causes had signiﬁcantly better survival than men with or without
coronary disease as their primary cause of heart failure.
(J Am Coll Cardiol 1996;28:1781–8)
1996 by the American College of Cardiology
Cardiovascular disease in women has attracted increasing
attention because epidemiologic and clinical trial data suggest
potential differences in natural history and response to therapy
between women and men. Most work has concentrated on
ischemic heart disease, and gender differences in risk of
ischemic complications have been found by some investigators
(1,2). However, the possibility of gender differences in heart
failure now assumes importance, given the emergence of this
condition as a major cardiovascular problem (3). Women, as
well as men, with heart failure still have high mortality and
morbidity rates despite treatment advances (4). Studies suggest
that the clinical expression of heart failure could be affected by
gender-related disparities in cardiac function and adaptation
that have been observed in the laboratory (5–8), during aging
(9) and in patients with aortic stenosis (10), hypertension (11)
and heart failure (12). Whether these physiologic differences
signiﬁcantly alter the clinical expression and outcome of heart
failure in men versus women continues to be debated.
Many previous studies (13–19) have related a variety of
demographic, clinical and physiologic characteristics to poor or
favorable long-term prognosis in patients with heart failure.
However, there is signiﬁcant conﬂict between the two most
important studies concerning the relation between gender and
outcome. The population-based Framingham Heart Study
(20,21) results suggest that the prognosis of women is signiﬁ-
cantly better than men after the onset of symptomatic heart
failure. In contrast to these epidemiologic data, Bourassa et al.
(22) reported a poorer outcome in women than men present-
ing with symptomatic heart failure during short-term (1 year)
follow-up based on the Studies of Left Ventricular Dysfunction
(SOLVD) Registry experience. Additional studies to resolve
these discrepant ﬁndings have not been reported.
To readdress this controversy, we studied whether the
clinical expression and outcome of heart failure differed be-
tween men and women and whether gender was an indepen-
dent risk factor for mortality after adjustment for gender
differences in left ventricular function and ischemic etiology.
We addressed these questions using information from the
UNC Heart Failure Database, University of North Carolina.
This prospective, long-term study observed the natural history
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of patients with heart failure at our institution, approximately
a third of whom were women.
Methods
The UNC Heart Failure Program, a referral practice at the
University of North Carolina devoted to the evaluation and
management of patients with heart failure, was initiated in
1984 by one of the authors (K.F.A.). Since that time, selected
data on baseline clinical characteristics and outcome in pa-
tients seen by the program have been prospectively collected
into the UNC Heart Failure Database. Collection methods for
the study data were approved by the institutional Committee
for the Protection of the Rights of Human Subjects. Entry into
this data base required a diagnosis of heart failure based on at
least one of the following: shortness of breath at rest or on
exertion or ﬂuid retention (edema, orthopnea or paroxysmal
dyspnea) that was believed to originate from cardiac causes (23).
Patients had a clinical examination to determine demo-
graphics, New York Heart Association functional class and
assignment of a primary etiology for their left ventricular
dysfunction. Signs and symptoms of heart failure and current
medications were recorded from history and physical exami-
nation performed in our Heart Failure Clinic or during a
previous hospital admission for heart failure. A standard
12-lead electrocardiogram was available within 6 months of
study entry for 96% of patients. Patients enrolled from July
1984 through November 1994 who had data on left ventricular
ejection fraction obtained by radionuclide ventriculography
within 6 months of study entry (91% within 1 month) were
considered for this report. Two patients whose heart failure
was complicated by other medical diseases (one with advanced
scleroderma and another with severe obstructive lung disease)
likely to signiﬁcantly limit their longevity were subsequently
excluded.
The majority of patients received their chronic heart failure
care in our clinic. Their therapy was optimized according to
general guidelines used in heart failure centers at the time of
the patient’s enrollment. However, treatment varied in indi-
vidual cases and was not rigorously standardized as in a clinical
trial. Beginning in September of 1986, heart transplantation
was considered as a therapeutic option in patients who met
standard criteria for this procedure. Vital status and the
occurrence of heart transplantation were ascertained at last
follow-up from contact with the patient, a family member or
the referring physician. All heart transplantation procedures
and hospital admissions resulting in urgent transplantation
occurred at our institution. Information concerning the pa-
tient’s demise, obtained from available medical records and
the patient’s attending physician or the family, was used by the
study physicians to assign a cause of death. Sufﬁcient follow-up
data for determining vital status were available for 99% of
patients (six women and one man were lost to follow-up). The
cause of death was unknown in one female and three male
patients. The mean length of follow-up was 2.4 years (range 1
day to 10 years).
Documentation of coronary disease. Angiographic, au-
topsy and clinical data were used to establish the presence (188
patients) or absence (369 patients) of coronary artery disease
in the study cohort. Coronary artery disease was identiﬁed in
156 patients on the basis of angiographic (147 patients) or
autopsy (9 patients) evidence of 70% stenosis of at least one
major epicardial coronary artery. Previous myocardial infarc-
tion documented by standard ECG or enzymatic criteria
established the diagnosis of coronary disease in another 29
patients. In three patients, the diagnosis of ischemic heart
disease was based on the presence of typical angina and a stress
radionuclide examination consistent with ischemia. Coronary
artery disease was judged absent in the remaining 369 study
patients. In 194 of these patients, coronary angiography re-
vealed no signiﬁcant obstructive lesions, and autopsy results
were negative in another 16. The remaining 159 patients were
judged not to have coronary artery disease according to the
following clinical criteria: no evidence of previous myocardial
infarction by history or ECG ﬁndings; no history of angina
pectoris; and the presence of an alternative etiology of heart
failure.
Assignment of etiology. Available clinical, laboratory and
autopsy data were utilized to assign a primary etiology for
heart failure in each patient. When multiple etiologic factors
were present, the one judged to be predominant was identiﬁed
as the primary cause. Ischemic heart disease was assigned as
the primary etiology in 162 of 188 patients with the diagnosis of
coronary artery disease. All 129 patients assigned hypertension
as the primary etiology of their heart failure had a history of
this disorder and evidence of either 1) antihypertensive phar-
macologic treatment, or 2) documentation of blood pressure
140 mm Hg systolic or90 mm Hg diastolic on at least three
separate occasions before or within 3 months after their entry
date (24). A primary etiology of hypertension was assigned
only after exclusion of other speciﬁc causes of cardiomyopathy
detailed later. Alcohol-related cardiomyopathy was designated
in 70 patients with a history of excessive ethanol intake
documented by a daily ingestion of 75 g of alcohol for 1 year
(25). Another 13 patients, with heavy but unquantiﬁable
alcohol use and social evidence of serious ethanol abuse (trafﬁc
violation or attendance at Alcoholics Anonymous) were also
assigned alcohol as a primary etiology. Valvular heart disease
was denoted as the primary etiology in 29 patients on the basis
of the presence of longstanding tricuspid, mitral or aortic
regurgitation documented by physical examination and echo-
cardiography or angiography. Peripartum cardiomyopathy was
diagnosed in 14 patients in whom the symptoms of heart
Abbreviations and Acronyms
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ECG  electrocardiogram
RR  relative risk
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failure developed at delivery (2 patients) or within 6 months of
delivery (12 patients).
Other rare causes of heart failure, including familial (11
patients), myocarditis (9 patients), chemotherapy (6 patients)
and congenital heart disease (5 patients), were assigned as the
primary etiology in 43 patients. Idiopathic cardiomyopathy was
designated as the primary etiology in the 97 study patients in
whom no apparent cause of heart failure was found. Coronary
angiographic (63 patients) or autopsy data (8 patients) ruled
out ischemic heart disease as the primary etiology in 71 of
these patients. The following primary etiologic groups were
thus identiﬁed: ischemic heart disease (162 patients), hyper-
tension (129 patients), alcohol related heart disease (83 pa-
tients), valvular heart disease (29 patients), idiopathic cardio-
myopathy (97 patients) and other (57 patients).
Radionuclide ventriculography. Patients underwent rest
equilibrium radionuclide ventriculography by techniques pre-
viously described in our laboratory (26,27), and the majority
(92%) also underwent ﬁrst-pass imaging by standard methods,
as described by others (28). First-pass left ventricular images
were analyzed to determine left ventricular end-diastolic vol-
ume by a geometric method (28). This technique was shown in
our laboratory to correlate well (r  0.95) with angiographic
left ventricular end-diastolic volume determined in our cardiac
catheterization laboratory.
Statistical analysis. Data are presented as mean value 
SEM, unless otherwise indicated. Various demographic factors
and indexes of cardiac function were compared between men
and women by Student t test or the chi-square test. The
primary study end point was all-cause mortality, and the
principal secondary end point was death related to cardiovas-
cular causes. The cause of death was considered to be cardio-
vascular in the four study patients whose reason for death was
unknown. In analyses using the primary and secondary end
points, patients undergoing heart transplantation were consid-
ered alive and were censored at the time of operation. Because
a substantial number of patients underwent heart transplanta-
tion during the follow-up period, the following complementary
composite secondary end points were also examined: all-cause
mortality plus urgent heart transplantation and cardiovascular
death plus urgent heart transplantation. Heart transplantation
was deﬁned as urgent if the patient developed worsening heart
failure requiring hospital admission and inotropic support
before this surgical procedure. Cumulative survival curves
based on gender were constructed by Kaplan-Meier methods,
with differences between the curves tested for signiﬁcance by
the log-rank statistic (29). The Cox proportional hazards
regression method was used to determine the relation of
gender and other baseline characteristics to outcome (30,31).
The following variables, determined from the baseline evalu-
ation, were considered potential predictors of study end points:
gender, functional class, ischemic versus nonischemic primary
etiology of heart failure, race, age, left ventricular ejection
fraction, left ventricular end-diastolic volume index, left ven-
tricular end-systolic volume index, height, weight, body surface
area, body mass, presence of atrial ﬁbrillation and use of
antiplatelet therapy. A method similar to that reported by
Harrell et al. (31) was followed by grouping baseline charac-
teristics related to cardiac function and patient morphology
into clusters likely to be intercorrelated and relevant to the
same clinical phenomenon. A stepwise regression identiﬁed
any variables within each cluster that were likely to be signif-
icant. These variables and other baseline characteristics shown
to be univariate predictors of outcome with a signiﬁcance level
0.10 were then analyzed in a stepwise fashion to develop Cox
models of the study end points and to create an adjusted
survival curve for men and women. In addition, the effect of
race on the ﬁnal model was also evaluated by proportional
hazard methods. The uniformity of the association between
gender and outcome in various etiologic groups was assessed
by the likelihood ratio test from the proportional hazards
model (29).
Study patients. A total of 557 patients who met the criteria
for study entry were identiﬁed in the data base. The mean
(SD) age of the study patients was 51  14 years, (range 13
to 87), and approximately one-third were female (32%), and
53% were white. The majority of the patients were functional
class II (30%) or III (49%). Only 14 patients (2.5% of 557)
were assigned to functional class I at their baseline evaluation.
All patients met the study deﬁnition of heart failure, and 90%
had symptoms of both ﬂuid retention and dyspnea. A left
ventricular third heart sound was a common ﬁnding on phys-
ical examination (77%), and congestion, as evidenced by
jugular venous distension (46%) or rales (35%), was frequently
present. The primary cause of heart failure was judged to be
nonischemic in 68% of patients. Severe left ventricular dys-
function was typically present, with a mean (SD) left ventric-
ular ejection fraction of 25  13 in the study cohort and an
ejection fraction 40% in 86%.
Results
Baseline patient data. Men and women did not differ with
regard to functional class, but men were signiﬁcantly more
likely than women to be white, to have atrial ﬁbrillation on the
baseline ECG and to have ischemic heart disease as the
primary etiology of heart failure (Tables 1 and 2). Rest left
ventricular ejection fraction was signiﬁcantly higher in women
than men (Table 1). At baseline (Table 2), a similar proportion
of men and women were receiving angiotensin-converting
enzyme inhibitors (69% vs. 72%, p  0.419) and digoxin (69%
vs. 68%, p  0.834), whereas total diuretic use in men tended
to be higher than in women (82% vs. 75%, p  0.056). Men
were receiving antiplatelet therapy more frequently than
women (22% vs. 13%, p  0.016).
Table 3 compares selected baseline characteristics in men
and women by ischemic versus nonischemic etiology. Left
ventricular ejection fraction did not differ in men and women
when ischemic heart disease was the primary etiology of heart
failure, but women had a higher left ventricular ejection
fraction than men in the nonischemic group. Women were
older than men when the primary etiology was ischemic heart
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disease but ages were similar in patients with a nonischemic
etiology.
Outcome of men versus women. During the follow-up
period, 201 patients reached the primary study end point of
all-cause mortality (156 men, 45 women). In 180 patients (41
women, 139 men), death was attributed to cardiovascular
causes. Heart transplantation was deemed urgent in 57 (42
men, 15 women) of the 65 patients undergoing this procedure.
Life-table analysis demonstrated that female patients were
signiﬁcantly less likely to have a mortal event during follow-up
than male patients (p  0.001) (Fig. 1). Women survived
longer than men when the end point was cardiovascular
mortality (p  0.001). In addition, the composite end points of
all-cause mortality plus urgent heart transplantation, and
cardiovascular mortality plus urgent heart transplantation
were more likely to be reached by men than women during
follow-up (p  0.001 for both).
Predictors of outcome. A number of baseline characteris-
tics, in addition to gender, were univariate predictors of
all-cause mortality in the study cohort (Table 4). Atrial ﬁbril-
lation but not use of antiplatelet medication tended to be a
univariate predictor of outcome. Although indexes of body
habitus differed between men and women, proportional haz-
ards analysis of this cluster of variables and gender demon-
strated that only gender was signiﬁcantly related to outcome
(p  0.001). Initial multivariate analysis demonstrated that
female gender was associated with a better outcome after all
other signiﬁcant univariate predictors were accounted for
(adjusted relative risk [RR] of men vs. women for all-cause
mortality was 2.37, 95% conﬁdence interval [CI] 1.37 to 3.51,
p  0.001). Multivariate analysis also demonstrated that
functional class, age, left ventricular ejection fraction and
primary ischemic etiology of heart failure were independently
associated with all-cause mortality after adjustment for all
other signiﬁcant univariate variables (Table 5). In addition, the
ﬁnal predictive model was not altered when race was included
as part of the multivariate Cox analysis.
Further multivariate Cox proportional hazards analysis
demonstrated that the favorable association between female
gender and all-cause mortality was dependent on the etiology
of heart failure (p  0.008) (Tables 5 and 6). The risk of death
was similar for the subset of men and women with ischemic
heart disease as the primary cause of heart failure (n  162).
The relative risk of males versus females in this etiologic group
was1, but this difference was not signiﬁcant (men vs. women:
Table 1. Baseline Characteristics of Male and Female
Study Patients
Characteristic
Men
(n  380)
Women
(n  177)
p
Value
Age (yr) 52  0.7 49  1.1 0.031
White 58% (219) 44% (78) 0.003
History of
HTN 53% (202) 51% (91) 0.701
DM 21% (80) 24% (42) 0.477
CABG 16% (60) 5% (8) 0.001
Etiology of HF
Idiopathic 13% (48) 28% (49) 0.001
Alcohol 21% (78) 3% (5) 0.001
Ischemic 37% (142) 11% (20) 0.001
Valvular 4% (14) 9% (15) 0.018
Hypertensive 20% (76) 30% (53) 0.010
Other 5% (22) 19% (35) 0.001
IHD primary 37% (142) 12% (20) 0.001
AF 12% (45) 5% (9) 0.012
Body habitus
Height (cm) 178  0.42 163  0.54 0.001
(n  361) (n  171)
Weight (kg) 84  1.0 72  1.5 0.001
(n  361) (n  170)
Body mass (kg/ht2) 27  0.3 27  0.6 0.340
(n  361) (n  170)
LVEF (U) 24  0.6 29  1.1 0.001
(n  380) (n  177)
LVEDVI (ml/m2) 191  3.6 185  4.9 0.324
(n  357) (n  168)
LVESVI (ml/m2) 149  3.5 137  4.9 0.048
(n  357) (n  168)
Data presented are mean value SD or percent (number) of patients. AF
atrial ﬁbrillation; CABG  coronary artery bypass graft surgery; DM  diabetes
mellitus; HF  heart failure; HTN  hypertension; IHD  ischemic heart
disease; LVEF  left ventricular ejection fraction; LVEDVI  left ventricular
end-diastolic volume index; LVESI  left ventricular end-systolic volume index.
Table 2. Historical Data on Signs, Symptoms and Therapy for Heart
Failure in Male and Female Patients
Characteristic
Men
(%)
Women
(%)
p Value
(chi-square)
NYHA functional class 0.343
I 2 4
II 30 29
III 50 46
IV 18 21
Symptoms of
Dyspnea on exertion 90 92 0.475
Edema 51 59 0.085
Orthopnea 61 71 0.023
PND 48 48 0.974
Physical exam
Rales 36 32 0.337
JVD 45 47 0.527
S3 77 77 0.926
Pedal edema 39 46 0.119
Medication
Digitalis 69 68 0.834
Diuretic 82 75 0.056
ACE inhibitor 69 72 0.419
Long-acting nitrate 26 21 0.210
Hydralazine 7 8 0.650
Dobutamine 4 5 0.779
Calcium antagonist 8 6 0.413
Antiplatelet 22 13 0.016
Anticoagulant 27 31 0.444
Amiodarone 3 2 0.458
ACE  angiotensin converting enzyme; JVD  jugular venous distension;
NYHA  New York Heart Association; PND  paroxysmal nocturnal dyspnea;
S3  left ventricular S3 gallop.
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RR 0.85, 95% CI 0.45 to 1.61, p 0.651). In contrast, men had
a signiﬁcantly greater risk of death than women in the subset of
patients judged to have a nonischemic etiology of heart failure
(n  395; men vs. women: RR 2.36, 95% CI 1.59 to 3.51, p 
0.001). These ﬁndings are reﬂected in the adjusted survival
curves for men and women with ischemic and nonischemic
etiologies shown in Figure 2. The conﬁdence limit for the
relative risk of men versus women with heart failure primarily
associated with ischemic heart disease was distinct from that
found in patients with nonischemic heart failure (Fig. 3).
Because of the interrelation between etiology, gender and
outcome, additional analyses were undertaken using different
deﬁnitions of ischemic heart disease. Multivariate Cox propor-
tional hazards analysis was repeated, with ischemic heart
disease deﬁned as the presence (n 188) or absence (n 369)
of signiﬁcant coronary artery disease, whether this disease was
considered the primary cause of heart failure. The predictors
included in this model were gender, ischemic heart disease (as
previously deﬁned) functional class, left ventricular ejection
fraction and age (Table 5). Using this categorization, male
gender was associated with an increase in risk similar to that
observed in the principal study analysis (n  557; men vs.
women: RR 1.94, 95% CI 1.35 to 2.78, p  0.001). Again as in
the principal analysis, the relation between gender and out-
come tended to be linked to the primary etiology of heart
failure (p  0.162 for the gender–etiology interaction). Out-
come was similar in men and women with evidence of coronary
artery disease (n 188; men vs. women: RR 1.08, 95% CI 0.58
to 2.00, p  0.812). In contrast, men without coronary artery
disease had a greater risk than women (n  369; men vs.
women: RR 2.38, 95% CI 1.58 to 3.58, p  0.001).
Proportional hazards analysis was also performed in study
patients (n  395) in whom the presence or absence of
coronary artery disease was determined on the basis of invasive
methods (coronary angiography or autopsy) or the occurrence
of myocardial infarction. Male gender was associated with
poorer survival in this subset (men vs. women: RR 1.86, 95%
CI 1.11 to 3.15, p  0.020). Male gender was also associated
with an unfavorable prognosis in the remaining 162 patients
whose coronary artery disease status was determined by clini-
Table 4. Univariate Relation of Individual Baseline Characteristics
to All-Cause Mortality
Variable Chi-Square RR (95% CI) p Value*
NYHA functional class 30.2 1.76 (1.44–2.15) 0.001
LVEF (per 5 U) 24.5 0.85 (0.80–0.91) 0.001
Type of CM (IHD) 31.8 2.32 (1.73–3.11) 0.001
Gender (male) 24.7 2.23 (1.67–3.26) 0.001
Age (decade) 25.2 1.31 (1.18–1.46) 0.001
LVESVI (per 50 ml/m2) 23.8 1.30 (1.17–1.45) 0.001
LVEDVI (per 50 ml/m2) 14.2 1.23 (1.10–1.37) 0.001
Height (per 10 cm) 10.4 1.25 (1.09–1.42) 0.001
BSA 3.0 1.66 (0.94–2.93) 0.083
Body mass 1.7 0.98 (0.96–1.01) 0.195
Weight (per 5 kg) 0.2 1.01 (0.97–1.04) 0.666
Race (white) 1.0 1.15 (0.88–1.52) 0.322
AF 3.2 0.68 (0.45–1.03) 0.070
Antiplatelet therapy 0.1 0.98 (0.67–1.44) 0.924
*Cox proportional hazards model. BSA  body surface area; CI  conﬁ-
dence interval; CM  cardiomyopathy; RR  relative risk; other abbreviations
as in Tables 1 and 2.
Table 3. Comparison of Selected Clinical Characteristics in Men Versus Women by Ischemic or
Nonischemic Etiology*
IHD Primary Etiology Non-IHD Primary Etiology
Men
(n  142)
Women
(n  20) p Value
Men
(n  238)
Women
(n  157) p Value
Age (yr) (mean  SD) 58  0.9 64  2.0 0.025 48  0.9 47  1.1 0.529
NYHA functional class (%) 0.189 0.541
I 2 0 2 4
II 23 20 34 30
III 50 40 50 47
IV 25 40 14 19
LVEF (U) (mean  SD 23  0.8 24  2.9 0.575 24  0.8 29  1.2 0.001
*Men versus women within each etiologic group; p values reﬂect Student t test, except those for functional class,
which were computed using the chi-square statistic. Abbreviations as in Tables 1 and 2.
Figure 1. Kaplan-Meier estimates of survival for male and female
patients. p  0.001 by log-rank test. Women (circles) had a signiﬁ-
cantly better outcome during follow-up. Squares  men.
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cal criteria alone (men vs. women: RR 2.80, 95% CI 1.55 to
5.07, p  0.001).
Discussion
Clinical investigation suggests that the natural history and
response to therapy may differ in men and women with
cardiovascular disease (1,2). Although most work has concen-
trated on gender differences in ischemic heart disease, heart
failure of any cause is an important cardiovascular condition in
women. By conservative estimate, there are 1 million female
patients with heart failure in the United States today (3). Both
women and men continue to have high mortality and morbidity
from symptomatic failure despite treatment advances. An
increasing body of laboratory (5–8), and clinical research
(9–12) suggests there are gender-related differences in cardiac
function and myocardial adaptation to injury or stress. Avail-
able studies disagree as to whether these physiologic factors
result in different clinical characteristics and survival in men
and women with heart failure. Our investigation addresses
these conﬂicting results.
We found that women—not men—survived longer with
symptomatic heart failure. To clarify this association, we
examined the relation between gender and a number of clinical
characteristics of heart failure. We found two major differ-
ences. Men were more likely than women to have an ischemic
etiology of their heart failure, and left ventricular ejection fraction
was higher in nonischemic women than nonischemic men.
The survival advantage of women could have been due to
better left ventricular function. However, mortality was still
lower in women after Cox proportional hazards modeling
adjusted for baseline differences in left ventricular function. In
contrast, the association between gender and outcome was
related to the primary etiology of heart failure (Fig. 2).
Modeling revealed that survival was signiﬁcantly better in
Figure 2. Adjusted survival curves for male and female patients with
and without ischemic heart disease as the primary etiology of heart
failure. Cox proportional hazards method revealed a signiﬁcant inter-
action between ischemic etiology and the association between gender
and survival (p  0.008). Women without coronary artery disease as
the primary cause of heart failure had a signiﬁcantly better outcome
during follow-up. Open circles  women with ischemic cardiomyopa-
thy; solid circles  women with nonischemic cardiomyopathy; open
squares  men with nonischemic cardiomyopathy; solid squares 
men with ischemic cardiomyopathy.
Figure 3. Relative risks and 95 percent conﬁdence intervals for
all-cause mortality of men versus women in various patient groups.
Relative risks are adjusted for the variables shown in Table 5. An
interaction between gender, etiology and outcome is revealed. The risk
of men with nonischemic etiologies of heart failure is signiﬁcantly
greater than that of women with a similar etiology. In contrast, the
relative risk is similar in men and women with an ischemic etiology of
heart failure. IHD  ischemic heart disease; Pts  patients.
Table 5. Baseline Characteristics With Independent
Prognostic Value
Variable
Adjusted
Chi-Square RR (95% CI) p Value*
Gender (male) 13.0 1.90 (1.28–1.99) 0.001
Type of CM (IHD)† 7.8 1.58 (1.15–2.17) 0.001
NYHA functional class 17.6 1.60 (1.28–1.99) 0.001
LVEF (per 5 U) 11.7 0.89 (0.83–0.95) 0.001
Age (decade) 11.3 1.22 (1.09–1.37) 0.001
Interaction, type of
CM and gender
7.0 0.36 (0.17–0.77) 0.008
*Cox proportional hazards model. †Signiﬁcant predictor when modeling was
done before an interaction between gender and ischemic heart disease (IHD)
was considered. Abbreviations as in Tables 1, 2 and 4.
Table 6. Relative Risk of Men Versus Women in Subsets Deﬁned
by Interaction of Gender and Ischemic–Nonischemic Etiology
Subset
Adjusted
Chi-Square
RR
(95% CI) p Value
IHD vs. non-IHD
Women 14.1 3.82 (1.90–7.69) 0.001
Men 3.3 1.37 (0.98–1.92) 0.067
Men vs. women
IHD 0.3 0.85 (0.45–1.61) 0.615
Non-IHD 18.0 2.36 (1.59–3.51) 0.001
Abbreviations as in Tables 1 and 4.
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women than men when heart failure was due to nonischemic
causes but was similar in the two genders when the principal
etiology was ischemic heart disease. The conﬁdence interval of
the relative risk of women versus men with nonischemic
cardiomyopathy was well above unity and distinct from that of
patients with ischemic cardiomyopathy (Fig. 3). In contrast, the
survival of women with heart failure due to ischemic cardio-
myopathy did not appear to be longer than that for men with
this cause of heart failure.
Various causal factors were present in our patients with a
primary nonischemic origin of heart failure. Differences in
outcome between men and women may be limited to speciﬁc
etiologic factors within this broad group. Additional studies in
a larger cohort of men and women with speciﬁc etiologies of
heart failure will be needed to resolve this issue.
Origin of differences. Although our investigation does not
identify the reasons for the difference in outcome between men
and women with heart failure, a number of possibilities, both
demographic and physiologic, can be considered. Interestingly,
despite previous ﬁndings in coronary artery disease, our survival
analysis did not suggest an association between body habitus and
prognosis. Women may have survived longer simply because they
were identiﬁed earlier in the course of their disease. They
appeared to have a similar degree of symptomatic heart failure
but a better baseline level of left ventricular function than men.
We cannot rule out differences in follow-up treatment or compli-
ance with treatment that may have inﬂuenced the occurrence of
different outcomes in men and women.
Fundamental physiologic differences in the nature and
extent of myocardial hypertrophy and adaptation might also
play a role in the gender differences that we found (7,8).
Animal studies by Pfeffer et al. (6) suggest that the adverse
inﬂuence of a given degree of hypertrophy on cardiac function
is different in male and female spontaneously hypertensive
rats. Despite a similar degree of concentric hypertrophy, peak
stroke volume and end-diastolic volume indexes were similar
in control and 18 month old affected female rats. In contrast,
similarly aged affected male rats showed a signiﬁcant reduction
in peak stroke volume index and an increase in end-diastolic
volume index compared with age-matched control rats. Recent
work by Carroll et al. (10) suggests that gender may inﬂuence
left ventricular adaptation to the abnormal cardiac loading
conditions present in patients with aortic stenosis. In their
study of elderly patients with severe aortic stenosis, women
tended to have well preserved systolic function with less
ventricular dilation and hypertrophy than their male counter-
parts, even when indexes of cardiac function were normalized
for body surface area. Devereux et al. (11) have reported that
hypertensive women are more likely than hypertensive men to
have left ventricular hypertrophy when a gender-speciﬁc 97th
percentile upper limit of normal is used to deﬁne increased
myocardial mass. Echeverria et al. (12) also found that left
ventricular function is better preserved in women than men
presenting with congestive heart failure. The autopsy study of
Olivetti et al. (9) in patients free of cardiovascular disease
found that aging is associated with cardiac myocyte cell loss
and reactive hypertrophy in men but not women. Their ﬁnd-
ings suggest that the myocardium of men may be more
vulnerable to the effects of cardiac damage than that of women.
Although these laboratory ﬁndings are intriguing, additional
studies of the relation between outcome and ventricular structure
and function in men and women will be required.
Previous work: gender and survival. Our data may help to
reconcile the conﬂicting results of previous studies concerning
gender-related differences in the outcome of heart failure.
Early and recent epidemiologic data from the Framingham
cohort (20,21) suggest that prognosis in women is better than
that in men after the development of heart failure. These
results are consistent with our ﬁndings because the majority of
Framingham study patients appear to have developed heart
failure primarily from nonischemic causes. In addition, our
data suggesting an inﬂuence of etiology on the association
between gender and survival may help to explain the results of
Bourassa et al. (22). Their study showed that female gender
was associated with a poor prognosis but in a population of
older patients with heart failure primarily due to coronary
artery disease. Several other previous series (32–38) in patients
with symptomatic heart failure have found an inconsistent
relation between gender and outcome. However, the majority
of these studies lacked statistical power to detect a gender-
related difference in mortality and did not take into account
the association between etiology and the inﬂuence of gender
on outcome observed in our work.
Limitations of the study. There are several potential limi-
tations to our study. The presence or absence of coronary
artery disease was determined in a number of patients on the
basis of clinical criteria alone. However, our analysis suggests
that the association between gender, etiology and survival did
not depend on the method of deﬁning ischemic heart disease.
Female gender predicted better survival when ischemic heart
disease was expanded to include the presence or absence of
coronary artery disease without regard for the patient’s pri-
mary etiology of heart failure. Additionally, a favorable asso-
ciation between female gender and outcome was found in
those study patients in whom angiography and autopsy results
or the occurrence of myocardial infarction was used to deter-
mine the presence or absence of ischemic heart disease.
The small number of women with ischemic heart disease
limits the strength of our conclusions concerning survival in
men and women in this etiology group. Although the point
estimate in this subset was close to 1, the conﬁdence interval
was wide, and we cannot fully rule out a survival difference
between the two genders in this etiologic group. The higher
early mortality of women after myocardial infarction might
have been expected to select a group of women who would
have a better outcome than men with chronic ischemic heart
failure (2). Clearly, additional long-term investigation of a
larger cohort of patients with heart failure due to ischemic
heart disease is warranted to determine whether risk is indeed
similar in men and women.
The generalizability of our results could be questioned
because our investigation was conducted at a single center and
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enrolled patients who were relatively young. We cannot rule
out the possibility that a different relation between gender and
outcome would have been found in a wider geographic area or
among geriatric patients. Acknowledging this potential limita-
tion, our study did enroll a relatively high proportion of women
and African-Americans, constituting a demographic spectrum
not commonly found in clinical trial data sets. Data concerning
other important prognostic factors, including plasma norepi-
nephrine and exercise capacity, would be of great interest but
were not consistently available in our patients. Additional
investigation is needed to determine whether these factors
account for the gender difference in survival that we observed.
Conclusions. Our study results support the hypothesis that
survival differs between women and men with symptomatic
heart failure. Our data suggest a relation between female
gender and better outcome but one that depends on the
primary etiology of heart failure. Women survived longer than
men when heart failure was due to nonischemic causes, but
mortality did not appear to differ substantially when heart
failure was due to coronary artery disease. Further studies in
larger groups of men and women are needed to clarify gender
differences in survival in speciﬁc nonischemic etiologies of
heart failure. Better understanding of the mechanisms contrib-
uting to the improved prognosis of women with nonischemic
cardiomyopathy may enhance future clinical investigation and
drug development for symptomatic ventricular dysfunction.
We gratefully acknowledge the manifold efforts in manuscript preparation
provided by Jean Cox and the astute editorial advice of Carol Winkelman.
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